

**PENAMBATAN MOLEKULER DERIVAT KUERSETIN
SEBAGAI SENYAWA ANTIKANKER PAYUDARA
SECARA *IN SILICO***

SKRIPSI

**FAUZIA NURUL IZZAH
A211093**



**SEKOLAH TINGGI FARMASI INDONESIA
YAYASAN HAZANAH
BANDUNG
2025**

**PENAMBATAN MOLEKULER DERIVAT KUERSETIN
SEBAGAI SENYAWA ANTIKANKER PAYUDARA
SECARA *IN SILICO***

SKRIPSI

Sebagai salah satu syarat untuk memperoleh gelar Sarjana Farmasi

**FAUZIA NURUL IZZAH
A211093**



**SEKOLAH TINGGI FARMASI INDONESIA
YAYASAN HAZANAH
BANDUNG
2025**

**PENAMBATAN MOLEKULER DERIVAT KUERSETIN
SEBAGAI SENYAWA ANTIKANKER PAYUDARA
SECARA *IN SILICO***

**FAUZIA NURUL IZZAH
A211093**

Juli 2025

Disetujui oleh:

Pembimbing



Dr. Syarif Hamdani, M.Si.

Pembimbing



Umi Baroroh, S.Si., M. Biotek.

Kutipan atau saduran baik sebagian ataupun seluruh naskah, harus menyebut nama pengarang dan sumber aslinya, yaitu Sekolah Tinggi Farmasi Indonesia.

Skripsi ini saya persembahkan kepada kedua orangtua saya yang sangat saya cintai, ayah dan mamah, serta kedua adik tersayang yang membantu dalam mendukung selesainya studi saya di bidang farmasi ini. Semoga dengan selesainya skripsi ini saya bisa terus melangkah menjadi pribadi yang lebih baik dan bisa menjadi kebanggaan kalian semua.

ABSTRAK

Kuersetin adalah flavonoid alami yang telah terbukti memiliki aktivitas biologis, salah satunya adalah sebagai agen antikanker. Derivat yang digunakan pada penelitian ini diantaranya pentametil kuersetin, pentaasetat kuersetin, dan pentabenzil kuersetin. Penelitian ini bertujuan untuk mengevaluasi aktivitas antikanker payudara dari derivat kuersetin melalui metode penambatan molekuler terhadap tujuh reseptor kanker payudara, yaitu ER α , PR, HER2, HAC, PD-L1, FGFR, dan IGFR. Proses penambatan molekuler dilakukan menggunakan *AutodockTools* dan dianalisis lebih lanjut dengan *BIOVIA Discovery Studio Visualizer*. Validasi penambatan molekuler menunjukkan RMSD < 2 Å, menandakan bahwa metode yang digunakan valid. Hasil penambatan molekuler menunjukkan bahwa derivat pentabenzil kuersetin memiliki afinitas tertinggi, terutama terhadap reseptor ER α (-13,23 kcal/mol; 200,89 pM), HAC (-13,78 kcal/mol; 78,76 pM), dan PD-L1 (-12,55 kcal/mol; 633,59 pM); derivat pentaasetat kuersetin menunjukkan hasil penambatan yang baik terhadap reseptor HER2 (-10,16 kcal/mol; 35,68 nM); derivat pentametil kuersetin tidak memiliki hasil penambatan yang paling baik terhadap semua reseptor.

Kata kunci: kuersetin, derivat, kanker payudara, penambatan molekuler

ABSTRACT

Quercetin is a natural flavonoid that has been proven to possess biological activities, one of which is its anticancer potential. The derivatives used in this study include pentamethyl quercetin, pentaacetate quercetin, and pentabenzyl quercetin. This research aims to evaluate the breast cancer inhibitory activity of quercetin derivatives through molecular docking against seven breast cancer receptors, namely ER α , PR, HER2, HAC, PD-L1, FGFR, and IGFR. The molecular docking process was performed using AutoDockTools and further analyzed with BIOVIA Discovery Studio Visualizer. The docking validation showed an RMSD < 2 Å, indicating that the method used is valid. The molecular docking results revealed that the pentabenzyl quercetin derivative had the highest affinity, particularly towards receptors ER α (-13,23 kcal/mol; 200,89 pM), HAC (-13,78 kcal/mol; 78,76 pM), and PD-L1 (-12,55 kcal/mol; 633,59 pM); the pentaacetate quercetin derivative showed strong binding to the HER2 receptor (-10,16 kcal/mol; 35,68 nM); the pentamethyl quercetin derivative did not show the best binding results for any of the receptors.

Keywords: *quercetin, derivative, breast cancer, molecular docking.*

KATA PENGANTAR

Bismillahirrahmanirrahim,

Segala puji dan syukur dipanjatkan ke hadirat Allah SWT atas limpahan rahmat, berkah, dan ridho-Nya sehingga penelitian dan penulisan skripsi yang berjudul **“Penambatan Molekuler Derivat Kuersetin Sebagai Senyawa Antikanker Payudara Secara In Silico”** dapat diselesaikan di bawah bimbingan Dr. Syarif Hamdani, M.Si. dan Umi Baroroh, S.Si., M.Biotek.

Penelitian dan penulisan skripsi ini dilakukan untuk memenuhi salah satu syarat untuk mendapatkan gelar sarjana pada Program Studi Sarjana Farmasi Sekolah Tinggi Farmasi Indonesia.

Pada kesempatan ini, ucapan terima kasih yang sebesar-besarnya tidak lupa disampaikan kepada:

1. Dr. apt. Adang Firmansyah, M.Si., selaku Ketua Sekolah Tinggi Farmasi Indonesia,
2. Dr. apt. Diki Prayugo, M.Si., selaku Wakil Ketua I Bidang Akademik,
3. Dr. apt. Hesti Riasari, M.Si., selaku Ketua Program Studi Sarjana Farmasi,
4. Umi Baroroh, S.Si., M.Biotek. selaku Dosen Wali yang telah banyak memberikan bimbingan dan arahan kepada penulis,
5. Serta sahabat-sahabat angkatan 2021 yang telah memberikan inspirasi dan kegembiraan selama penulis kuliah di Sekolah Tinggi Farmasi Indonesia.

Dalam penyusunan skripsi ini masih banyak kesalahan dan kekurangan karena pengetahuan yang masih sangat terbatas. Oleh karena itu, dengan kerendahan hati diharapkan masukan berupa kritik dan saran yang bersifat membangun untuk perbaikan di masa yang akan datang. Diharapkan bahwa tugas akhir ini dapat memberikan manfaat bagi pembaca maupun bagi pihak lain yang berkepentingan.

Bandung, Juli 2025

Fauzia Nurul Izzah

DAFTAR ISI

LEMBAR PENGESAHAN	i
KUTIPAN	ii
PERSEMBAHAN	iii
ABSTRAK	iv
<i>ABSTRACT</i>	v
KATA PENGANTAR	vi
DAFTAR ISI	vii
DAFTAR TABEL	ix
DAFTAR GAMBAR	x
DAFTAR LAMPIRAN	xi
I. PENDAHULUAN	1
1.1 Latar Belakang	1
1.2 Identifikasi Masalah	2
1.3 Tujuan Penelitian	2
1.4 Kegunaan Penelitian	3
1.5 Tempat dan Waktu Penelitian	3
II. TINJAUAN PUSTAKA	4
2.1 Kuersetin	4
2.2 Kanker Payudara	5
2.2.1 Subtipe Kanker Payudara	6
2.3 Derivatisasi	7
2.4 Reseptor Target	8
2.4.1 Reseptor Estrogen Alfa (ER α)	8
2.4.2 Reseptor Progesteron (PR)	9
2.4.3 <i>Human Epidermal Growth Factor Receptor 2</i> (HER2)	10
2.4.4 <i>Human Aromatase Cytochrome P450</i> (HAC P450)	10
2.4.5 <i>Programmed Death-1 Receptor</i> (PD-1) dan <i>Programmed Death</i> <i>Ligan 1 Receptor</i> (PD-L1)	10
2.4.6 <i>Fibroblast Growth Factor Receptor</i> (FGFRs)	11
2.4.7 <i>Insulin Growth Factor-1 Receptor</i> (IGF-1R)	11
2.5 Penambatan Molekuler	12
III. TATA KERJA	13
3.1 Alat	13
3.2 Bahan	13
3.3 Metode Penelitian	17
3.3.1 Persiapan Reseptor dan Ligan	17

3.3.2	Validasi Metode	17
3.3.3	Penambatan Derivat Kuersetin.....	17
3.3.4	Analisa dan Visualisasi Hasil Penambatan	18
IV.	HASIL PENELITIAN DAN PEMBAHASAN	19
4.1	Preparasi Ligan dan Reseptor.....	19
4.2	Validasi Metode Penambatan Molekuler	20
4.3	Hasil Penambatan Molekuler	21
V.	SIMPULAN DAN ALUR PENELITIAN SELANJUTNYA.....	32
5.1	Simpulan.....	32
5.2	Alur Penelitian Selanjutnya.....	32
	DAFTAR PUSTAKA	33
	LAMPIRAN	38

DAFTAR TABEL

Tabel	Halaman
2.1 Subtipe Kanker Payudara.....	6
3.1 Struktur Reseptor.....	13
3.2 Struktur Ligan.....	16
4.1 Hasil Validasi Metode.....	20
4.2 Hasil Penambatan Molekuler Ligan Asli, Kuersetin, serta Derivatnya Terhadap Tujuh Reseptor Kanker.....	21
4.3 Nilai Ki Ligan Asli, Kuersetin, dan Derivatnya Terhadap Tujuh Protein Target Kanker.....	22

DAFTAR GAMBAR

Gambar	Halaman
2.1 Struktur Kuersetin.....	4
4.1 Hasil Prediksi IBM RXN untuk Derivat (a) Pentametil Kuersetin (b) Pentaasetat Kuersetin (c) Pentabenzil Kuersetin.....	20
4.2 Visualisasi Interaksi Ligan Pentabenzil Kuersetin dengan Reseptor ER α	23
4.3 Visualisasi Interaksi (a) Ligan Kuersetin (b) Ligan Pentametil Kuersetin dengan Reseptor PR.....	24
4.4 Visualisasi Interaksi Ligan Pentaasetat Kuersetin dengan Reseptor HER2.....	25
4.5 Visualisasi Interaksi (a) Ligan Pentaasetat Kuersetin (b) Ligan Pentabenzil Kuersetin dengan Aromatase.....	26
4.6 Visualisasi Interaksi (a) Ligan Pentaasetat Kuersetin dan (b) Ligan Pentabenzil Kuersetin dengan Reseptor PD-L1.....	27
4.7 Visualisasi Interaksi (a) Ligan Pentaasetat Kuersetin dan (b) Ligan Pentabenzil Kuersetin dengan Reseptor FGFR.....	29
4.8 Visualisasi Interaksi Ligan Pentaasetat Kuersetin dengan Reseptor IGFR.....	30

DAFTAR LAMPIRAN

Lampiran	Halaman
1. Visualisasi Interaksi Senyawa Uji pada Tujuh Reseptor Kanker.....	38
2. Hasil Penambatan Molekuler.....	48
3. Alur Kerja Penelitian.....	55

DAFTAR PUSTAKA

- Aertgeerts, K., Skene, R., Yano, J., Sang, B. C., Zou, H., Snell, G., Jennings, A., Iwamoto, K., Habuka, N., Hirokawa, A., Ishikawa, T., Tanaka, T., Miki, H., Ohta, Y., & Sogabe, S. (2011). Structural Analysis of The Mechanism of Inhibition and Allosteric Activation of The Kinase Domain of HER2 Protein. *Journal of Biological Chemistry*, 286(21), 18756–18765. <https://doi.org/10.1074/jbc.M110.206193>
- Agu, P. C., Afiukwa, C. A., Orji, O. U., Ezeh, E. M., Ofoke, I. H., Ogbu, C. O., Ugwuja, E. I., & Aja, P. M. (2023). Molecular Docking as a Tool for The Discovery of Molecular Targets of Nutraceuticals in Diseases Management. *Scientific Reports*, 13(1), 1–18. <https://doi.org/10.1038/s41598-023-40160-2>
- Alamri, A., Rauf, A., Khalil, A. A., Alghamdi, A., Alafnan, A., Alshammari, A., Alshammari, F., Malik, J. A., & Anwar, S. (2021). In Silico Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen Receptor Alpha-Positive Breast Cancer. *BioMed Research International*, 2021. <https://doi.org/10.1155/2021/9734279>
- Anand, D., Alexander, V., Arulmoli, R., & Parasuraman, S. (2016). Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid. *Pharmacognosy Reviews*, 10(20), 84–89. <https://doi.org/10.4103/0973-7847.194044>
- Arnesen, S., Blanchard, Z., Williams, M. M., Berrett, K. C., Li, Z., Oesterreich, S., Richer, J. K., & Gertz, J. (2021). Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects. *Cancer Research*, 81(3), 539–551. <https://doi.org/10.1158/0008-5472.CAN-20-1171>
- Baroroh, U., Sin, C. W. Y., & Riasari, H. (2023). Exploration Of Potential Natural Compounds Through In Silico Approach: A Case Study On Tokaramid Compounds. *Jurnal Sains Dan Teknologi Farmasi Indonesia*, 12(2), 86–101.
- Batiha, G. E. S., Beshbishy, A. M., Ikram, M., Mulla, Z. S., Abd El-Hack, M. E., Taha, A. E., Algammal, A. M., & Ali Elewa, Y. H. (2020). The Pharmacological Activity, Biochemical Properties, and Pharmacokinetics of The Major Natural Polyphenolic Flavonoid: Quercetin. *Foods*, 9(3). <https://doi.org/10.3390/foods9030374>
- Borrelli, W. R., & Schrier, J. (2021). Evaluating the Performance of a Transformer-based Organic Reaction Prediction Model. In *Department of Chemistry Fordham University*. <https://rxn.res.ibm.com>
- Chan, H. J., Petrossian, K., & Chen, S. (2016). Structural and Functional Characterization of Aromatase, Estrogen Receptor, and Their Genes in Endocrine-

- Responsive and – Resistant Breast Cancer Cells. *J Steroid Biochem Mol Biol*, 5(161), 1–26. <https://doi.org/10.1016/j.jsbmb.2015.07.018>. Structural
- Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023). A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. *International Journal of Molecular Sciences*, 24(7). <https://doi.org/10.3390/ijms24076834>
- Ding, S., Ullah, I., Gong, S. Y., Grover, J. R., Mohammadi, M., Chen, Y., Vézina, D., Beaudoin-Bussièrès, G., Verma, V. T., Goyette, G., Gaudette, F., Richard, J., Yang, D., Smith, A. B., Pazgier, M., Côté, M., Abrams, C., Kumar, P., Mothes, W., ... Baron, C. (2022). VE607 Stabilizes SARS-CoV-2 Spike in The “RBD-up” Conformation and Inhibits Viral Entry. *IScience*, 25(7), 1–20. <https://doi.org/10.1016/j.isci.2022.104528>
- Dongliao, F., Zhigang, H., Xinyang, X., Xiaoyan, D., & Liu, Z. (2022). Key Signal Transduction Pathways and Crosstalks in Cancer: Biological and Therapeutic Opportunities. *Translational Oncology*, 26(101510), 1–7.
- Dourado, J. de A. E., Lopes, S. Q., Jimenez, D. E. Q., Ramos, R. S., & Ferreira, I. M. (2025). Identification of Novel Progesterone Receptor (PR) Inhibitors (Homo sapiens) from Metabolites of Biotransformation Fungal: A Bioinformatics Approach. *Pharmaceuticals*, 18(2), 1–14. <https://doi.org/10.3390/ph18020136>
- Ghosh, D., Griswold, J., Erman, M., & Pangborn, W. (2009). Structural Basis for Androgen Specificity and OEstrogen Synthesis in Human Aromatase. *Nature*, 457(7226), 219–223. <https://doi.org/10.1038/nature07614>
- Guzik, K., Tomala, M., Muszak, D., Konieczny, M., Hec, A., Błaszkiwicz, U., Pustuła, M., Butera, R., Dömling, A., & Holak, T. A. (2019). Development of the Inhibitors That Target the. *Molecules*, 24(2071), 1–30.
- Guzik, K., Zak, K. M., Grudnik, P., Magiera, K., Musielak, B., Törner, R., Skalniak, L., Dömling, A., Dubin, G., & Holak, T. A. (2017). Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. *Journal of Medicinal Chemistry*, 60(13), 5857–5867. <https://doi.org/10.1021/acs.jmedchem.7b00293>
- Ivanova, L., & Karelson, M. (2022). The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy. *Molecules*, 27(9041).
- Kawasaki, Y., & Freire, E. (2011). Finding A Better Path To Drug Selectivity. *NIH Public Access*, 23(1), 1–12. <https://doi.org/10.1016/j.drudis.2011.07.010>. Finding
- Kim, M., Park, Y., Cho, S., Burapan, S., & Han, J. (2015). Synthesis of Alkyl Quercetin Derivatives. *Journal of the Korean Society for Applied Biological Chemistry*, 58(3), 343–348. <https://doi.org/10.1007/s13765-015-0050-x>
- Kimura, Y., Kato, R., Oyama, K. I., Kondo, T., & Yoshida, K. (2016). Efficient Preparation of Various O-Methylquercetins by Selective Demethylation. *Natural*

- Product Communications*, 11(7), 957–961.
<https://doi.org/10.1177/1934578x1601100722>
- Li, Z., Wei, H., Li, S., Wu, P., & Mao, X. (2022). The Role of Progesterone Receptors in Breast Cancer. *DovePress*, 16(January), 305–314. https://doi.org/10.1007/978-1-4615-3876-9_8
- Łukasiewicz, S., Czaczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanislawek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers*, 13(17), 1–30.
- Massi, A., Bortolini, O., Ragno, D., Bernardi, T., Sacchetti, G., Tacchini, M., & De Risi, C. (2017). Research Progress in the Modification of Quercetin Leading to Anticancer Agents. *Molecules*, 22(8). <https://doi.org/10.3390/molecules22081270>
- Messaoudi, O., Sudarman, E., Patel, C., Bendahou, M., & Wink, J. (2022). Metabolic Profile, Biotransformation, Docking Studies and Molecular Dynamics Simulations of Bioactive Compounds Secreted by CG3 Strain. *Antibiotics*, 11(5). <https://doi.org/10.3390/antibiotics11050657>
- Monteiro, M., Zhang, X., & Yee, D. (2024). Insulin Promotes Growth in Breast Cancer Cells Through the Type I IGF Receptor in Insulin Receptor Deficient Cells. *Experimental Cell Research*, 434(1), 113862. <https://doi.org/10.1016/j.yexcr.2023.113862>
- Paterni, I., Granchi, C., Katzenellenbogen, J., & Minutolo, F. (2014). Estrogen Receptors Alpha and Beta Subtype-Selective Ligands and Clinical Potential. *NIH Public Access*, 0, 13–29. <https://doi.org/10.1016/j.steroids.2014.06.012>. Estrogen
- Pradipta, I. S., Aprilio, K., Febriyanti, R. M., Ningsih, Y. F., Pratama, M. A. A., Indradi, R. B., Gatera, V. A., Alfian, S. D., Iskandarsyah, A., & Abdulah, R. (2023). Traditional Medicine Users in a Treated Chronic Disease Population: a Cross-Sectional Study in Indonesia. *BMC Complementary Medicine and Therapies*, 23(1), 1–9. <https://doi.org/10.1186/s12906-023-03947-4>
- PubChem. (2024). *Compound Summary: Quercetin*. NCBI PubChem.
- Rajesh R, U., & Dhanaraj, S. (2023). A Critical Review on Quercetin Bioflavonoid and its Derivatives: Scope, Synthesis, and Biological Applications with Future Prospects. *Arabian Journal of Chemistry*, 16(8), 104881. <https://doi.org/10.1016/j.arabjc.2023.104881>
- Rosen, L. S., Ashurst, H. L., & Chap, L. (2010). Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review. *The Oncologist*, 15(3), 216–235. <https://doi.org/10.1634/theoncologist.2009-0145>
- Santolla, M. F., & Maggiolini, M. (2020). The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives. *Cancers*, 12(10), 1–20.

- <https://doi.org/10.3390/cancers12103029> Schütz, F., Stefanovic, S., Mayer, L., Von Au, A., Domschke, C., & Sohn, C. (2017). PD-1/PD-L1 Pathway in Breast Cancer. *Oncology Research and Treatment*, 40(5), 294–297. <https://doi.org/10.1159/000464353>
- Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998). The Structural Basis of Estrogen Receptor/Coactivator Recognition and The Antagonism of This Interaction by Tamoxifen. *Cell*, 95(7), 927–937. [https://doi.org/10.1016/S0092-8674\(00\)81717-1](https://doi.org/10.1016/S0092-8674(00)81717-1)
- Soni, N., Pardasani, K. R., & Mujwar, S. (2015). Insilico Analysis of Dietary Agents as Anticancer Inhibitors of Insulin Like Growth Factor 1 Receptor (IGF1R). *International Journal of Pharmacy and Pharmaceutical Sciences*, 7(9), 191–196.
- Tucker, J. A., Klein, T., Breed, J., Breeze, A. L., Overman, R., Phillips, C., & Norman, R. A. (2014). Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4. *Structure*, 22(12), 1764–1774. <https://doi.org/10.1016/j.str.2014.09.019>
- Varakumar, P., Rajagopal, K., Islam, F., Raman, K., Byran, G., Gurunathan, M., Prema, S., Murugesan, T., Chitrapu, P., Barua, R., Ahmad, S. F., Attia, S. M., & Emran, T. Bin. (2023). Identifying Potent 9-Anilinoacridine-Based HER2 Breast Cancer Inhibitors Using in Silico Computational Approaches. *Journal of Biological Regulators and Homeostatic Agents*, 37(12), 6511–6523. <https://doi.org/10.23812/j.biol.regul.homeost.agents.20233712.616>
- Walle, T. (2009). Methylation of Dietary Flavones Increases Their Metabolic Stability and Chemopreventive Effects. *International Journal of Molecular Sciences*, 10(11), 5002–5019. <https://doi.org/10.3390/ijms10115002>
- Wang, G., Wang, Y., Yao, L., Gu, W., Zhao, S., Shen, Z., Lin, Z., Liu, W., & Yan, T. (2022). Pharmacological Activity of Quercetin: An Updated Review. *Evidence-Based Complementary and Alternative Medicine*, 2022, 1–12. <https://doi.org/10.1155/2022/3997190>
- Wang, J., & Wu, S. G. (2023). Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives. *Breast Cancer: Targets and Therapy*, 15(October), 721–730. <https://doi.org/10.2147/BCTT.S432526>
- Wang, R., Yang, L., Li, S., Ye, D., Yang, L., Liu, Q., Zhao, Z., Cai, Q., Tan, J., & Li, X. (2018). Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM). *Medical Science Monitor*, 24, 412–420. <https://doi.org/10.12659/MSM.908022>
- Wang, X., Simpson, E. R., & Brown, K. A. (2015). Aromatase Overexpression in Dysfunctional Adipose Tissue Links Obesity to Postmenopausal Breast Cancer. *ScienceDirect*, 153, 35–44.

- Watkins, E. J. (2019). Overview of Breast Cancer. *Journal of the American Academy of Physician Assistants*, 32(10), 13–17. <https://doi.org/10.1097/01.JAA.0000580524.95733.3d>
- WHO. (2025). *Mapping The Application of Artificial Intelligence in Traditional Medicine* (World Health Organization & International Telecommunication Union (ed.)).
- Williams, S., & Sigler, P. (1998). Atomic Structure of Progesterone Complexed with Its Receptor. *Nature*, 393(28), 392–396. <https://doi.org/10.1038/246170a0>
- Wu, D., Guo, M., Philips, M. A., Qu, L., Jiang, L., Li, J., Chen, X., Chen, Z., Chen, L., & Chen, Y. (2016). Crystal structure of the FGFR4/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455. *PLoS ONE*, 11(9), 1–11. <https://doi.org/10.1371/journal.pone.0162491>
- Zhang, W., Sun, J., Zhang, P., Yue, R., Zhang, Y., Niu, F., Zhu, H., Ma, C., & Deng, S. (2024). Design, Synthesis and Antitumor Activity of Quercetin Derivatives Containing a Quinoline Moiety. *Molecules*, 29(1), 1–11. <https://doi.org/10.3390/molecules29010240>
- Zubair, M. S., Anam, S., Maulana, S., & Arba, M. (2021). In Vitro and In Silico Studies of Quercetin and Daidzin as Selective Anticancer Agents. *Indonesian Journal of Chemistry*, 21(2), 310–317. <https://doi.org/10.22146/ijc.53552>